Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

Deepmind scientist raises $50m to use AI in protein design revolution

by February 16, 2025
February 16, 2025
Deepmind scientist raises $50m to use AI in protein design revolution

A former DeepMind scientist who helped develop AlphaFold, the AI model that revolutionised protein structure prediction, has raised $50 million to launch Latent Labs, a startup focused on using artificial intelligence to design new proteins.

Simon Kohl, a German-born physicist and machine learning expert, founded Latent Labs in 2023 with the ambition of “achieving computational mastery over biology.” The company aims to partner with biotech firms to accelerate drug development by replacing traditional experimental methods with AI-driven protein design.

The funding round, completed in December, was led by Radical Ventures, an AI-focused investment fund, alongside Sofinnova Partners, known for its life-sciences investments. High-profile backers include: Jeff Dean – Google’s chief scientist, Aidan Gomez – co-founder of generative AI firm Cohere and Mati Staniszewski – co-founder of AI audio startup ElevenLabs.

With an earlier $10 million in start-up capital, Latent Labs has now secured a total of $50 million to scale its operations.

Kohl, 34, previously worked at DeepMind, where he played a key role in the second iteration of AlphaFold—technology that has been recognised with a Nobel Prize in Chemistry. While AlphaFold enables scientists to map existing protein structures, Kohl believes the next step is to design new proteins from scratch using generative AI.

“[AlphaFold] allows you to look at the catalogue of existing natural proteins, but it doesn’t allow you to make new ones,” said Kohl.

His goal with Latent Labs is to develop AI models that eliminate the need for traditional laboratory techniques, making drug discovery faster and more precise.

Latent Labs is assembling a team of top AI and biotech researchers across London and San Francisco, including four former DeepMind scientists. The company is actively hiring more specialists as it expands.

By applying generative AI to protein and molecular design, Kohl believes Latent Labs can reduce failures in clinical trials, a key challenge in the pharmaceutical industry.

“There are still lots of failures in clinical trials, and in some ways, you can trace the issue back to how the drug was originally discovered,” he explained.

“If you can design proteins and molecules with a higher degree of control and precision, the idea is that in the future, we will see fewer failures.”

Kohl acknowledged concerns over the ethical implications of AI-generated proteins, calling it “an important question” that requires broader discussion. However, he stressed that current AI technology is not yet advanced enough to surpass what human experts can achieve in a well-equipped lab.

As for when Latent Labs’ AI will outperform traditional methods, Kohl admitted it was difficult to predict.

“Our north star is that our AI systems will eventually be so advanced that they no longer require experimental lab validation,” he said. “At that point, you will have quite powerful technology on your hands.”

Latent Labs is entering a competitive but still emerging field where multiple startups are exploring how AI can reshape drug development. Kohl compared the landscape to a space race.

“It feels like quite a number of rockets are being launched right now, and they may all reach orbit,” he said.

While Latent Labs has not disclosed its current projects or clients, the startup’s rapid funding and high-profile backing suggest it is poised to be a key player in the future of AI-driven drug discovery and protein engineering.

Read more:
Deepmind scientist raises $50m to use AI in protein design revolution

0
FacebookTwitterGoogle +Pinterest
previous post
GOP rep who returned to Congress after eight-year break credits Trump with unifying party
next post
Third of UK entrepreneurs fear Trump’s proposed tariffs will hit business costs

You may also like

Tech chiefs debate cyber threat in Parliament

June 13, 2023

UK inflation falls to 8.7 per cent in...

May 24, 2023

Rishi Sunak’s stealth tax to cost middle earners...

November 2, 2022

When Accountability Fades: The Toxic Reality Facing Bramley...

September 20, 2024

How Eric J. Hannon’s Experience in the United...

March 14, 2023

Hybrid working poses a risk to high-trust organisations

August 9, 2023

Novo Executive Search and Selection celebrates its 20th...

September 20, 2023

Commercial vehicle output records best May since 2008

June 30, 2023

Cutting-edge projects secure £6.6m investment to strengthen the...

September 13, 2023

Boris Johnson rules out immediate cost-of-living measures

August 9, 2022

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Week Ahead: NIFTY’s Behavior Against This Level Crucial As The Index Looks At Potential Resumption Of An Upmove

      June 7, 2025
    • FLASHBACK: Musk accused Trump, GOP leaders of not wanting to cut spending — here’s where they said they would

      June 7, 2025
    • ‘Right down the line’: Medicaid reform in ‘big, beautiful bill’ divides lawmakers by party

      June 7, 2025
    • FAST distribution and IA

      June 7, 2025
    • Why Independent Digital Platforms Are Gaining Ground Among UK Entrepreneurs

      June 7, 2025
    • Is Decentralisation the Future of Online Services in the UK?

      June 7, 2025

    Categories

    • Business (8,152)
    • Investing (2,019)
    • Politics (15,560)
    • Stocks (3,135)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved